Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Obexelimab in IgG4-Related Disease
NCT05662241Phase 3Active, not recruiting
- Sponsor
- Zenas BioPharma
- Start
- Jan 2023
- Primary completion
- Nov 2025
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 15
01
Overview
Phase 3, randomised, double-blind trial in IgG4-related disease (IgG4-RD) comparing Obexelimab with Placebo (2 arms). Primary endpoint: Time to First IgG4-RD Flare Requiring Rescue Therapy at 52 weeks. Started Jan 2023; status: active, not recruiting.
02
Drugs
obexelimab
03
Conditions
IgG4-related disease (IgG4-RD)
Beyond the preview
Go deeper on NCT05662241.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05662241.